Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Jigucao is a Traditional Chinese Medicine (TCM) formulation, primarily available in capsule form, developed and marketed by Conchen Pharmaceutical (a subsidiary of Consun Pharmaceutical Group). It is indicated for the treatment of liver and gallbladder diseases associated with damp-heat patterns in TCM, such as acute and chronic hepatitis and cholecystitis. The formulation typically contains *Abrus cantoniensis* (Jigucao) as the primary ingredient, often combined with other herbs like *Artemisia capillaris* (Yinchen), *Gardenia jasminoides* (Zhizi), and *Panax notoginseng* (Sanqi) to clear heat, detoxify, and soothe the liver. It is widely used in China for its hepatoprotective and choleretic properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Jigucao.